Relmada Therapeutics (RLMD) 8-K Other Events

Exhibit 99.1

Relmada Therapeutics, Inc.

Proforma Balance Sheet

March 31, 2019

Unaudited

				March 31, 2019
				Pro Forma
		Without		Adjustments			Post pro-
		Impact of		Resulting from			Forma
		Financings		Financings			Adjustments
				($ in thousands)
Assets:
Current	$	2,330,300	$	10,855,700	a	$	13,186,000	b
Non-current		273,427		-			273,427
Total assets		2,603,727		10,855,700			13,459,427
Liabilities and stockholders’ equity:
Current		2,129,829		-			21,459,427
Non-current		-		-			-
Total Liabilities		2,129,829		-			2,129,829
Stockholders’ equity		473,898		10,855,700			11,329,598
Total liabilities and stockholders’ equity	$	2,603,727	$	10,855,700		$	13,459,427

(a) This is the adjustment to account for the net proceeds from the financing transactions that occurred on 5/14/19, 6/14/2019, 6/20/19 and 6/28/2019

(b) This is the proforma Balance sheet as if the net proceeds from the financing transactions (noted above) had happened on 3/31/2019